Biocept to Participate in Three Virtual Investment Conferences in March
March 09 2021 - 7:00AM
Business Wire
Company presentation features neuro-oncology
program with goal of becoming standard of care for diagnosis,
characterization and monitoring of metastatic spread of solid
tumors to the central nervous system (CNS)
Provides update on COVID-19 testing with more
than 300,000 samples received
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that President
and CEO Michael Nall will participate in three upcoming virtual
investment conferences:
- H.C. Wainwright Global Life Sciences Virtual Conference
being held March 9-10, 2021. Biocept will hold virtual investor
meetings. Investors can request a meeting by registering for the
H.C. Wainwright Global Life Sciences Virtual Conference here.
- 33rd Annual Roth Conference being held March 15-17,
2021. Biocept will hold virtual investor meetings. Investors
interested in arranging a virtual meeting should contact their Roth
Capital Partners sales representative or LHA Investor Relations. A
webcast of Biocept’s presentation has been pre-recorded and is
available on the Company’s website here. Roth Conference
information is available here.
- Maxim 2021 Emerging Growth Virtual Conference being held
March 17-19, 2021. Biocept will participate in a fireside chat
hosted by Maxim Group Senior Managing Director Jason McCarthy,
Ph.D. on Friday, March 19 at 1:30 p.m. Eastern time. Investors can
register for the conference here.
Biocept’s corporate presentation is available on the Company’s
website here.
“Our presentations highlight progress with our neuro-oncology
initiative and strategy to become the standard of care when
diagnosing and monitoring the spread of cancer into the CNS,” said
Mr. Nall. “While pursuing this goal, our team continues to serve
our community and help fight the pandemic with COVID-19 RT-PCR
testing, having now received more than 300,000 COVID-19 samples
since June 2020. We are excited about the opportunity to expand our
RT-PCR COVID-19 testing portfolio under our recently announced
supply agreement with Aegea Biotechnologies to develop a
differentiated, quantitative laboratory developed test (LDT).”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers, including metastatic tumors involving lung,
breast and the central nervous system. Biocept’s patented Target
Selector™ technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity
and specificity than most commercial assays. Additionally, Biocept
is leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 PCR testing to support public health efforts
during this unprecedented pandemic. For additional information,
visit www.biocept.com. Follow Biocept
on Facebook, LinkedIn and Twitter.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. To the extent that statements in this release
are not strictly historical, including without limitation
statements regarding our ability to become standard of care for
diagnosis, characterization and monitoring of metastatic spread of
solid tumors to the CNS, our ability to expand our RT-PCR COVID-19
testing portfolio under our recently announced supply agreement
with Aegea Biotechnologies, and the ability of Biocept’s liquid
biopsy technology to provide physicians with clinically actionable
information, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risks and uncertainties,
including the risk that our products and services may not perform
as expected. These and other risks are described in greater detail
under the "Risk Factors" heading of our Quarterly Report on Form
10-Q for the quarter ended September 30, 2020, as filed with the
Securities and Exchange Commission (SEC) on November 16, 2020. The
effects of such risks and uncertainties could cause actual results
to differ materially from the forward-looking statements contained
in this release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210309005299/en/
Investors: LHA Investor Relations Jody Cain
Jcain@lhai.com 310-691-7100
Media: Sampson PR Group Andrea Sampson
asampson@sampsonprgroup.com 562-304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Sep 2023 to Sep 2024